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Feline leukemia virus (FeLV) subgroup B arises de novo through recombination between the env genes of exogenous FeLV
subgroup A and endogenous FeLV-like sequences. FeLV-B, which by itself is poorly infectious, will increase to high titer in
the presence of FeLV-A, and is associated with FeLV-related neoplastic disease. Although the participation of FeLV-B in
disease progression has not been definitively proven, circumstantial evidence supports the hypothesis that the generation
of FeLV-B is linked to disease progression. The present study was designed to evaluate whether increasing the levels of
FeLV-B early in FeLV-A infection could result in reduction of the incubation period for development of neoplastic disease. For
this study, an isolate of FeLV-B, designated FeLV-1B3, was biologically cloned, partially sequenced, and subgroup typed. In
in vivo studies, none of the neonatal cats inoculated with FeLV-1B3 alone converted to viremia positive, and all remained
healthy throughout the observation period. All of the kittens inoculated with FeLV-A alone became chronically viremic, and
those held for long-term observation all developed either neoplastic disease or anemia. However, kittens inoculated with the
combination of FeLV-1B3 and FeLV-A showed attenuated infections whereby the majority of cats failed to develop chronic
viremia. The apparent interference of FeLV-A infection by FeLV-B was time and titer dependent. This unexpected result
suggests that FeLV-B may act as an attenuated virus, causing inhibition of FeLV-A possibly through an immune-mediated
mechanism. Partial support for this view was provided by postmortem examination of cats inoculated with FeLV-1B3 alone.
Even though none of these cats became viremic, FeLV antigen was detected as focal infections in select tissues, especially
salivary gland epithelium, where enough antigen may be expressed to provide an immunizing dose against gag and pol
cross-reacting antigens. This work may also provide another approach to vaccine development based on endogenous
retrovirus vector systems. © 2000 Academic PressINTRODUCTION
Feline leukemia viruses (FeLVs) belong to subgroup A, B,
or C, based on superinfection interference properties
(Jarrett et al., 1978a; Sarma and Log, 1971, 1973). Natural
infections are predominantly subgroup A (FeLV-A), whereas
subgroup B arises de novo as a result of recombination
between exogenous FeLV-A and endogenous FeLV-like
(en-FeLV) env sequences that are expressed in select nor-
mal feline cells as full-length transcripts (McDougall et al.,
1994; Busch et al., 1983). En-FeLV contains frameshift mu-
tations and stop codons within gag, thus preventing trans-
lation of the gag/pol polyprotein (Soe et al., 1985). Delineat-
ing the recombinational events between subgroup A and
endogenous FeLV has been the focus of a number of
reports (Elder and Mullins, 1983; Soe et al., 1983; Over-
baugh et al., 1988; Kumar et al., 1989; Pandey et al., 1991;
Sheets et al., 1993; Rohn et al., 1994; Tsatsanis et al., 1994;
1 Present address: Battelle Memorial Institute, 505 King Avenue,
olumbus, OH 43201.
2 To whom correspondence and reprint requests should be ad-
dressed at The Ohio State University, Center for Retrovirus Research,
1925 Coffey Road, Columbus, OH 43210. Fax: (614) 292-6473. E-mail:
mathes.2@osu.edu.
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
40Roy-Burman, 1996; Bechtel et al., 1998; Chen et al., 1998).
Part of this work addresses the receptor requirements for
subgroups A and B. Although the receptor for subgroup A is
unknown, the receptor for FeLV-B has been identified as the
sodium-phosphate symporter (Pit) present on feline and
nonfeline cells (Boomer et al., 1997; Rudra-Ganguly et al.,
1998). During FeLV-A/en-FeLV recombination, acquisition of
a portion of the en-FeLV env sequence converts progeny
virus from subgroup A to subgroup B (Pit1or Pit2) receptor
usage. The coordinates of endogenous env substitution
required for Pit recognition by subgroup B viruses were
previously described (Boomer et al., 1997).
Epidemiological studies showed that subgroup B FeLV
can be isolated from 30 to 60% of FeLV-infected cats but
only in conjunction with subgroup A, suggesting that
horizontal transmission of subgroup B FeLV alone occurs
rarely, if at all (Jarrett et al., 1978a; Hardy et al., 1976; Neil
et al., 1991). Interestingly, subgroup B FeLVs are overrep-
resented in cats that develop FeLV-associated lym-
phoma (Roy-Burman, 1996). Molecular analysis of natu-
rally occurring feline FeLV-associated lymphomas indi-
cated that 64% of tumors contained FeLV subgroup
A/endogenous env gene recombinants, which are pre-
dicted to be “subgroup B-like” by sequence analysis
(Sheets et al., 1993; Tsatsanis et al., 1994). In our inves-
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41INHIBITION OF FeLV-A INFECTION BY FeLV-B COINOCULATIONtigations, FeLV recombinants were detected in buffy coat
or bone marrow DNA by PCR analysis as early as 1 to 2
weeks after FeLV subgroup A plasmid DNA inoculation
of neonatal cats, and infectious recombinant progeny
viruses were detected in plasma by interference analysis
at about 8 weeks postinoculation (p.i.) (Chen et al., 1998;
Phipps et al., 2000). However, the role of subgroup B
FeLV in the pathogenic process that is a sequela to
subgroup A FeLV infection and the subsequent recom-
bination events with en-FeLV remain to be better delin-
eated.
Limited data exist as to the in vivo infectivity and
pathogenic nature of subgroup B FeLVs in the absence
of subgroup A coinfection. Subgroup B FeLVs are fully
replication competent in vitro in both feline and certain
nonfeline cell lines (Sarma et al., 1975; Jarrett et al., 1973;
Hardy et al., 1980). However, cats seem to be highly
resistant to infection with cell-free subgroup B viruses
alone (Bechtel et al., 1999) and subgroup B FeLVs appear
to require helper FeLV-A viruses for successful transmis-
sion (Jarrett and Russell, 1978b). One possible explana-
tion for this paradox may be viral interference by en-FeLV
SU protein expression. Because FeLV-like endogenous
SU is closely related to the SU of subgroup B FeLV, the
Pit1 or Pit2 receptor used by FeLV-B may be blocked by
the endogenous SU protein. En-FeLV SU expression has
been documented in feline tissues and the feline lym-
phoma cell line 3201 (McDougall et al., 1994). Thus, the
distribution of the Pit receptors on suitable target cells
and simultaneous endogenous FeLV SU expression on
these cells in vivo may limit subgroup B virus infection.
However, it is unclear how the presence of FeLV-A pro-
motes FeLV-B transmission in vivo.
Because FeLV-B is poorly infectious alone but often
arises de novo to become a prominent constituent of the
viral population, particularly in association with neoplas-
tic disease, there may be some selective purpose for
FeLV-B in disease progression. We hypothesized that, if
the concentration of subgroup B virus were to be artifi-
cially increased early in infection, a more rapid progres-
sion of FeLV-associated disease might follow. Therefore,
the present studies were undertaken to (1) evaluate the
infectivity and pathogenic nature of a natural biological
clone of subgroup B FeLV that arose de novo following
subgroup A infection, and (2) ascertain whether coinocu-
lation with subgroups A and B results in enhanced dis-
ease progression when compared to cats inoculated
with subgroup A FeLV alone.
RESULTS
Biological cloning of naturally occurring subgroup B
FeLV recombinants
The terminal plasma sample, collected from a cat that
died of lymphoma 28 weeks after infection with pFRA
DNA (FeLV-A), was shown to contain both FeLV-A and
t
pFeLV-B by direct interference assay. To isolate subgroup
B virus, a portion of the plasma sample was inoculated
into human HT-1080 fibrosarcoma cells, which are per-
missive to FeLV-B but not to FeLV-A (Jarrett et al., 1973;
Sarma et al., 1975). Limiting dilution was used to select
clonal populations of HT-1080 cells with integrated FeLV
subgroup B proviruses. Twelve of the resulting clones
were evaluated for relative virus output by ELISA and for
FeLV subgroup present by direct interference assay.
Clones 1B2, 1D2, 1A3, 1B3, and 1D3 were tested in a
second direct interference assay, which revealed that
only clone 1B3 was FeLV subgroup B alone. Cell-free
virus lots designated FeLV-1B3 were generated from
expanded cell cultures. Multiple lots of virus from the 1B3
clone collected over the subsequent year and tested by
direct interference assay were all subgroup B only.
Molecular analysis of the FeLV-1B3 LTR and env
genes
The FeLV-1B3 LTR was amplified by PCR from
genomic DNA isolated from the HT-1080 1B3 clone. DNA
sequence analysis of the LTR revealed a transition (C to
T) at position 161 and a transversion (G to C) at position
415 compared to the parental FRA molecular clone (data
not shown). The FeLV-1B3 env gene was amplified by
CR from genomic DNA isolated from the HT-1080 1B3
lone. Six primers spanning the SU were used for DNA
equence analysis. Comparison of the FeLV-1B3 and
ndogenous CFE-6 (accession no. M21479) (Kumar et al.,
989) deduced amino acid sequences revealed a 59
ecombination site 19 amino acids downstream of the
tart of SU (gp70) (Fig. 1). The 39 recombination site
ccurred at site C (Sheets et al., 1993), which resulted in
he incorporation of endogenous FeLV variable regions
–3. Comparison of FeLV-1B3 with the predicted amino
cid sequence of FeLV-FRA, the parent subgroup A chal-
enge virus, revealed five amino acid substitutions out-
ide the recombination region, four of which were unique
o the 1B3 isolate (Fig. 1).
eLV-B/FeLV-A coinfection studies
The overrepresentation of subgroup B FeLV in cats
hich developed FeLV-associated lymphoma (Jarrett et
l., 1978a), and the presence of subgroup B FeLV in our
xperimental cats which developed tumors, led us to
ypothesize that coinoculation of subgroup B FeLV with
xogenous subgroup A FeLV would further enhance neo-
lastic disease progression. The first experiment was a
ong-term pathogenesis study comprised of three groups
f cats (Groups A, B, and C; Table 1). As expected, none
f the Group A cats inoculated with FeLV-1B3 alone (0 of
hree cats) developed viremia. The fourth cat in Group A
ied at 4 weeks of age of a congenital defect unrelatedo virus challenge but was FeLV negative up to that time
oint. Also, as expected, all of the Group B cats inocu-
t
V ce. The
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42 PHIPPS ET AL.lated with FeLV-A alone (four of four) became FeLV pos-
itive. One of these animals was euthanized at 10 weeks
of age for humanitarian reasons relating to a hip defor-
mity. FeLV antibody responses for Group A were low,
reaching peak titers of 1:40 in the first 14 weeks for the
FIG. 1. Aligned amino acid sequences of the SU region for the subg
he endogenous FeLV clone CFE-6 (accession no. M21479). The met
ariable regions 1–5 (VR1–VR5) are denoted by a line above the sequen
he region of endogenous envelope substitution for the FeLV-1B3 isol
T
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Group
Challeng
FeLV-A
Experiment 1 A —
B neonate
C neonate
Experiment 2 D —
E neonate
F neonate
G neonate
a Cats were inoculated by intradermal route with FeLV-A consisting
(4.5 3 107 ffu) or low-titer (5 3 106 ffu) FeLV-1B3.
b Time of challenge was either neonatal (24 to 48 h postpartum) or
c FeLV status was determined by detection of FeLV p27 in plasma u
d One kitten from Group A and one kitten from Group B were euthanized
challenge.three remaining cats (data not shown). The antibody
responses for Group B cats were similar to those of
previous reports (Chen et al., 1998), reaching peak titers
of 1:640–1:1280 in the first 14 weeks (data not shown).
The results of the combined challenge (FeLV-A 1 FeLV-
FeLV clone FRA (accession no. AF052723), the FeLV-1B3 isolate, and
residues of the signal peptide and gp70 are indicated with arrows.
39 recombination junction sites A–G (Sheets et al., 1993) are in boxes.
haded, showing the 59 and 39 recombination junctions.
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43INHIBITION OF FeLV-A INFECTION BY FeLV-B COINOCULATION1B3, Group C) were unanticipated. Only two of five cats
inoculated with FeLV-A, followed 14 days later by FeLV-
1B3, became viremic, suggesting that in some cats FeLV-
1B3 inhibited the FeLV-A challenge. Antibody responses
for Group C cats ranged between 1:10 and 1:320 in the
14-week period following challenge, showing that there
was some degree of virus replication in vivo (data not
shown).
Experiment 1 cats were held for up to 84 weeks p.i.
None of the cats in Group A developed clinical signs of
FeLV-related disease, while all of the three surviving cats
in Group B developed lymphoma or anemia and were
euthanized between 43 and 58 weeks p.i. Of the FeLV-
positive cats in Group C, one developed thymic lym-
phoma and the others, anemia at 27 and 13 weeks p.i.,
respectively. The three FeLV-negative cats in Group C
remained clinically normal for the duration of the study
(84 weeks).
Based on the unexpected observations from Experi-
ment 1 and to exclude the possibility that the result from
limited numbers of animals was a “litter effect,” a second
short-term experiment was designed. Experiment 2 was
similar in design to Experiment 1 but used a different lot
of FeLV-1B3 and each group contained cats from multiple
litters. Because Lot 4 and several other lots of 1B3 were
lower titer than Lot 3 used in Experiment 1, we increased
the volume of the challenge dose to 3 ml per cat. Even
so, the titer of the challenge dose was approximately 1
log below that used in Experiment 1. In Experiment 2, the
results from Groups D and E were identical to those of
Groups A and B, respectively. None of the Group D cats
(FeLV-1B3 alone) developed viremia (0 of seven), but had
peak antibody titers between 1:80 and 1:640 (not shown).
All of Group E cats (FeLV-A alone) became viremic (six of
six) with peak antibody titers of 1:80 to 1:320 (not shown).
Group F cats, which received a similar challenge to
Group C except for the low-titer FeLV-1B3 (FeLV-A at
24–48 h postpartum 1 FeLV-1B3 14 days later), failed to
how any significant inhibition of FeLV-A infection, with
nly one cat remaining negative at 8 weeks p.i., and this
at wavered between negative and positive on subse-
uent blood collections. Peak antibody titers in this
roup ranged between 1:320 and 1:1280 (not shown). In
roup G (FeLV-A 1 low-titer FeLV-1B3, both inoculated
ogether at 24–48 h postpartum), however, five of seven
ats were protected from FeLV-A infection, once again
howing a similar inhibition pattern to Group C in Exper-
ment 1. Group G peak antibody titers were between 1:80
nd 1:320. Statistical analysis comparing the three co-
hallenged groups (Groups C, F, and G) with the FeLV-
-positive control groups (Groups B and E) revealed a
ignificant difference for Groups C (z-test, P 5 0.04;
isher exact test, P 5 0.022) and G (z-test, P 5 0.008;
isher exact test, P 5 0.003), in which FeLV viremia was
ndetectable in a total of eight out of 12 challenged cats
Group C 1 Group G).
z
dCombining the results from Experiments 1 and 2, the
ollowing interpretations emerge: (1) FeLV-1B3, even at
igh titer, is unable to induce chronic viremia in neonatal
ats (0 of 11 cats from three litters became viremic); (2)
eLV-A (pFRA) is highly infectious in neonatal cats (10 of
0 cats from three litters became viremic); (3) anti-FeLV
ntibody titers were not predictive of infection outcome;
nd (4) cochallenge experiments (FeLV-A 1 FeLV-B) sug-
est that FeLV-B attenuated the FeLV-A challenge in a
ose- and time-dependent manner. At high titer, FeLV-
B3 could be administered 2 weeks after the FeLV-A
hallenge and still cause a significant reduction in the
ncidence of FeLV-A-induced chronic viremia. The lower
iter of FeLV-1B3 was not protective when administered 2
eeks after inoculation with FeLV-A but did significantly
educe the incidence of viremia when administered si-
ultaneously with FeLV-A (five of seven cats from two
itters were protected).
ostmortem examination of tissues for FeLV-1B3-
hallenged cats
Tissues from Group E cats inoculated with low-titer
eLV-B3 were evaluated for focal FeLV antigen expres-
ion by immunofluorescence. FeLV antigen was detected
n the salivary gland of five of the six cats tested (Table
). FeLV antigen was also detected in the intestinal
pithelium of two cats, thymus of one cat, and marginal
TABLE 2
FeLV Antigen Distribution in Tissues from FeLV-1B3 Infected
Neonatal Cats (Group D) from Experiment 2
Tissue
Cat number
1 2 3 4 5 6 7
Brain 2a 2 2 2 2 2 2
Salivary gland 1 1 ndb 1 1 2 1
Tonsil 2 2 nd nd nd 2 nd
Thyroid nd nd 2 2 2 nd 2
Thymus 2 2 2 1 2 2 nd
ung 2 2 2 2 2 2 2
tomach 2 2 2 nd 2 2 2
ntestine 2 2 2 6 2 2
ancreas 2 2 2 2 2 2 2
ladder nd nd 2 2 1 2 1
idney 2 2 2 2 2 2 2
drenal gland 2 2 2 2 2 2 2
ymph node 2 2 2 2 2 nd 2
pleen 2 2 2 2 nd 2 1
one marrow 2 2 2 2 2 2 2
iver nd 2 2 2 2 2 2
uscle 2 2 2 2 2 2 nd
a Results are listed as 1 or 2 based on fluorescent antibody staining
eLV p27 of methanol-fixed tissue (Rojko et al., 1978).
b nd 5 not done; tissue was not available for examination.one of spleen of one cat (Table 2). No antigen was
etected in peripheral blood leukocytes, bone marrow,
44 PHIPPS ET AL.tonsil, lymph node, or any of the other tissues evaluated
(Table 2).
Evidence of recombination in cats coinoculated with
FeLV-A and FeLV-B
Plasma samples from the two cats that became FeLV
positive in Group C were analyzed for recombinant vi-
ruses by interference assay. Even though the cats re-
ceived both challenge virus subgroups in the first 2
weeks, only subgroup A could be detected in plasma for
the first 8 weeks p.i. One cat converted to the A/B
interference pattern at 12 weeks p.i., while the other
remained subgroup A only throughout the observation
period.
DISCUSSION
The purpose of this study was to determine whether
coinfection with subgroups A and B FeLV increases the
frequency of disease progression in inoculated cats. The
experimental design was based on the premise that the
de novo development of subgroup B was associated with
disease onset, particularly neoplastic disease. Counter
to our hypothesis, in Experiment 1 we observed that
coinfection with subgroups A and B did not enhance
pathogenesis, but that subgroup B coinoculation sup-
pressed subgroup A viremia.
We determined that the biological clone FeLV-1B3 had
limited replication in vivo but was capable of establishing
focal FeLV infections primarily of the salivary gland in
neonatal cats inoculated with the cell-free virus. How-
ever, neonatal cats that received either the high or low
dose of the FeLV-1B3 isolate alone remained nonviremic
and did not develop any FeLV-associated disease during
the 13- to 84-week observation period. As such, neonatal
cats are not truly resistant to subgroup B FeLV infection,
but develop a localized FeLV infection in the absence of
viremia.
Subgroup B FeLVs were also thought to depend on
associated FeLV-A viruses for successful transmission
(Jarrett and Russell, 1978b). Contrary to this hypothesis,
five of seven cats that were simultaneously inoculated
with the low titer of FeLV-1B3 and the FeLV-A were
protected from viremia and FeLV-associated disease.
Likewise, three of five cats inoculated with FeLV-A fol-
lowed by the high-titer FeLV-1B3 inoculation 2 weeks
later were protected. Furthermore, subgroup analysis of
the replicating FeLV isolated from two viremic cats coi-
noculated with FeLV-A/FeLV-1B3 did not reveal plasma
subgroup B FeLVs earlier than the 12 weeks’ time point
previously observed for pFRA- or pF6A-challenged cats
(Chen et al., 1998; Phipps et al., 2000). Likewise, FeLV-
associated disease development was not hastened
when compared to earlier studies involving cats inocu-
lated with two FeLV-A isolates alone (pFRA or pF6A)
(Chen et al., 1998; Phipps et al., 2000).These studies with the FeLV-1B3 isolate indicate that
exogenous delivery of subgroup B FeLVs may be insuf-
ficient for lymphoma induction, even when coinoculated
with helper subgroup A FeLVs. However, subgroup B
FeLVs are a component of the heterogeneous pool of
defective and nondefective de novo recombinant FeLVs,
formed by subgroup A FeLV and en-FeLV recombination,
which may be involved in the neoplastic transformation
of lymphoid target cells (Pandey et al., 1991; Sheets et al.,
1993; Rohn et al., 1994; Tsatsanis et al., 1994; Roy-Bur-
man, 1996; Bechtel et al., 1998; Chen et al., 1998).
The receptor for subgroup B FeLV is the sodium phos-
phate symporter Pit (-1or -2). Pit1 and Pit2 are expressed
on a wide range of somatic tissues (Johann et al., 1992;
Tatsumi et al., 1998). However, the accessibility of sub-
group B FeLV is thought to be blocked by coexpression
of en-FeLV SU glycoprotein. Thus, cells expressing en-
FeLV, which include spleen, small intestine, bone, thy-
mus, and lymph node (McDougall et al., 1994), are not
readily infected by subgroup B FeLV. Based on the pat-
tern of FeLV antigen distribution in FeLV-1B3-infected
cats, we predict that Pit but not en-FeLV is expressed on
the salivary gland and bladder epithelium of cats.
The mechanism by which FeLV-1B3 infection sup-
presses FeLV viremia following subgroup A FeLV infec-
tion is unknown. We postulate that the limited expression
of FeLV-1B3 in select tissues such as salivary gland may
act similarly to an attenuated infection characteristic of
many live virus vaccines. Thus, the limited infection by
FeLV-1B3 may induce an immune response capable of
protecting against pathogenic FeLV-A infection. Although
the antibody response to FeLV was relatively weak in
FeLV-1B3-inoculated cats, we have no information on the
cytotoxic T-cell response induced by FeLV-1B3. Because
the gag and pol genes of the FeLV-1B3 and the FeLV-A
molecular clones are presumed to be virtually identical,
infection by FeLV-1B3 may induce cross-protection
against FeLV-A. Additionally, localized FeLV-1B3 replica-
tion in nonlymphoid compartments without viremia is
unlikely to result in significant immunosuppression,
since we presume that low levels of p15E, the TM mol-
ecule with immunosuppresive properties (Mathes et al.,
1978, 1979), would not be present systemically.
In conclusion, the property of FeLV-1B3 to protect cats
from viremia and FeLV-associated disease demonstrates
the potential for endogenous viruses to interfere with
exogenous retrovirus infection and may have relevance
for novel vaccine development against retrovirus infec-
tion.
MATERIALS AND METHODS
Subgroup B FeLV isolation and biological cloning
FeLV subgroup B was initially isolated on feline em-
bryonic fibroblast cells (FEA) from the plasma of a cat
inoculated with FeLV-pFRA (Chen et al., 1998). After 21
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45INHIBITION OF FeLV-A INFECTION BY FeLV-B COINOCULATIONdays, clarified tissue culture fluids from the FEA cultures
tested positive for FeLV p27 by ELISA (Petcheck FeLV
ELISA; Synbiotics, San Diego CA), and were filtered and
then inoculated onto the human fibrosarcoma cell line
(HT-1080) in the presence of Polybrene (final concentra-
tion 4 mg/ml). The FeLV-inoculated HT-1080 bulk culture
was maintained for 3 weeks p.i. Twenty-four-well plates
were prepared by plating g-irradiated (100 Gy) uninfected
T-1080 cells at a density of 1000 cells/well to form a
eeder layer. The FeLV-infected HT-1080 cells were
dded to the wells containing the feeder layer at 3.0
ells/well. Wells exhibiting colony formation were
creened by FeLV p27 ELISA. Wells with detectable FeLV
27 were further screened by direct viral interference
ssay for subgroup determination. Viral interference as-
ays to identify FeLV subgroups were performed as pre-
iously described (Sarma and Log, 1973). FeLV
seudotypes of murine sarcoma virus were generated
ith virus stocks derived from molecular clones FeLV-A/
lasgow-1 (pFGA) (Stewart et al., 1986), FeLV-B/GA
pBHM-1) (Elder and Mullins, 1983), and FeLV-C/Sarma
pFSC) (Riedel et al., 1986). Cell-free FeLV-1B3 virus
tocks were titered with a focus-forming assay as previ-
usly published (Fischinger et al., 1974).
CR amplification and sequence analysis of LTR and
nv from the FeLV-1B3 isolate
Genomic DNA was isolated from the HT-1080-1B3 cells
y a commercial kit (Puregene DNA Isolation Kit; Gentra
ystems, Minneapolis, MN). The LTR PCR reaction mix
ontained 13 PCR buffer (BRL/Life Technologies, Rockville,
D), 2.0 mM MgCl2, 300 mM dNTPs, 80 ng each FeLV-
TR(Exo1) primer (59-TGAAAGACCCCCTACCCAAA-39) and
eLV-LTR(Exo2) (59-CAGCTTACCTCCTGATGGTG-39), 1.5 U
latinum Taq DNA polymerase (BRL/Life Technologies),
and 300 ng of DNA in a final volume of 50 ml. The env PCR
reaction contained 13 PCR buffer (BRL/Life Technologies),
1.5 mM MgCl2, 300 mM dNTPs, 75 ng each FeLV-Env1
primer (59-GG[G/A]CCAACCACC[G/A]ATCA[G/A]GACCT-39)
and FeLV-Env2 (59-TGCC[T/C]CCTAC[A/G]GTGA[T/G]TC-
CTCCC-39), 1.5 U platinum Taq DNA polymerase (BRL/Life
Technologies), and 300 ng of DNA in a final volume of 50 ml.
Samples were denatured at 94°C for 1.5 min then amplified
by 45 cycles of 94°C for 30 s, 60°C for 25 s, and 72°C for
39 s, followed by a final extension at 72°C for 5 min. PCR
products were purified by agarose gel electrophoresis and
extracted by a commercial gel extraction kit (Qiagen, Santa
Clarita CA). PCR products were utilized in automated DNA
sequencing reactions with the following LTR-specific prim-
ers: FeLV-LTR(Exo1) and FeLV-LTR(Exo2); and env-specific
primers: FeLV-Env1, FeLV-Env2, VR5B1 (59-GTGATATAGGT-
CTCTTCGG-39), VR5A1 (59-AACTAAGAGCTGTTGGCTC-
GC-39), FeLV-Env3 (59-TCTTTGGGA[C/T]GGACCTAAG[A/
][C/T][A/G]TGG-39), and FeLV-Env4 (59-ATAGGGTCATATC-
TG[A/T]ACGGTAT-39). Sequence data analysis was per-ormed with the DNAsis software package (Molecular Biol-
gy Insights, Cascade, CO).
eLV in vivo challenge
All cats used in this study were specific-pathogen-free
SPF) neonates between 24 to 48 h of age at the time of
irus challenge, unless indicated differently, and were
rom a commercial source (Liberty Research, Waverly,
Y). The results are from two separate in vivo studies
eferred to as Experiment 1 and Experiment 2. Cats were
ivided in seven groups (Groups A–G) (see Table 1).
roups A, B, and C were in Experiment 1; Groups D–G
ade up Experiment 2. Group A (four cats; High-Dose
hallenge) was inoculated by intraperitoneal route with 1
l of FeLV-1B3 Lot 3 (4.5 3 107 ffu/ml). Group B (four
ats) and Group E (six cats), which served as challenge
ontrol groups for Experiments 1 and 2, respectively,
ere inoculated by intradermal route with 50 mg of pFRA
lasmid DNA combined with a cationic lipid compound
DOTAP; Boehringer Mannheim, Indianapolis, IN) (Wil-
ems et al., 1993). Group C (five cats) was inoculated with
0 mg of pFRA plasmid DNA combined with DOTAP by
intradermal route 24–48 h postpartum and 2 weeks later
with the high-dose FeLV-1B3 (final dose 4.5 3 107 ffu).
Group D (seven cats; Low-Dose Challenge) was inocu-
lated intraperitoneally with 5 ml of FeLV-1B3 Lot 4 (1 3
106 ffu/ml). Group F (seven cats) was inoculated simul-
taneously with 50 mg of pFRA plasmid DNA combined
with DOTAP intradermally and low-dose FeLV-1B3 (final
dose 5 5.0 3 106 ffu). Group G (seven cats) was inocu-
ated with 50 mg of pFRA plasmid DNA combined with
DOTAP by intradermal route followed by the low-dose
FeLV-1B3 (5.0 3 106 ffu) inoculation by intraperitoneal
route on the same day (24–48 h postpartum). The kittens
remained with their own queens until weaning at 10
weeks of age and then were separated by sex and group
into one or two animals per cage. Once paired, cage
mates were not changed throughout the remainder of the
study. All work was performed in accordance with Uni-
versity Laboratory Animal Care and Use Committee and
by DHEW publication No. NIH 74-23, Guide for the Care
and Use of Laboratory Animals.
Antigen and antibody detection
FeLV antigenemia (presumptive viremia) was mea-
sured by antigen capture enzyme-linked immunosorbent
assay (Petcheck FeLV ELISA; Synbiotics) for the detec-
tion of p27 capsid protein in plasma. Optical density
(O.D.) readings (Abs 5 650 nm) for the FeLV p27 ELISA
were normalized by following formula: (O.D. unknown 2
O.D. kit negative)/(O.D. kit positive 2 O.D. kit negative).
Anti-FeLV antibody responses were detected by indirect
immunofluorescence on the FL-74 cat T-lymphoma cell
line chronically infected with FeLVs representing each of
the A, B, and C subgroups (Essex et al., 1971). Complete
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46 PHIPPS ET AL.necropsies were performed at the conclusion of each
study and tissue samples were collected and fixed in
either 10% neutral buffered Formalin or 100% methanol,
or snap-frozen in liquid nitrogen. Preserved tissues were
processed for histopathologic examination as well as
immunofluorescent antibody detection of FeLV antigens
in situ (Rojko et al., 1978).
Statistical analysis
Both Fisher exact test and z-test were performed with
the SigmaStat software package (Jandel Scientific, San
Rafael, CA).
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